Keywords: Vascular/Vessel Wall, Blood vessels, Contrast agents, vasculitis
Motivation: The newly developed contrast agent Gadopiclenol promises high contrast and substantial gadolinium saving potential which shall be realized in vasculitis vessel wall imaging.
Goal(s): To compare objective image quality of 0.05 mmol/kg Gadopiclenol with 0.1 mmol/kg standard dose Gadoteric acid in high resolution scalp arteries and aorta vessel wall imaging in vasculitis.
Approach: Normalized signal intensity and image quality of 3T MRI of 70 patients with suspected giant cell arteritis (25 Gadopiclenol, 45 Gadoteric acid) was compared.
Results: No significant differences of signal intensity of MRA (p>0.87) nor at post-contrast T1weighted SE images (p>0.37) were found between Gadopiclenol and Gadoteric acid scans.
Impact: Gadolinium usage could now be reliably reduced by half utilizing half dose Gadopiclenol while maintaining clinically needed high contrast in vasculitis imaging and aortic imaging, a previously unmet need by other contrast agents.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords